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Abstract 
 
 
 
 
 
 
 
Introduction: Major depressive disorder is one of the most prevalent psychiatric disorders and is 
associated with a severe impact on the personal functioning, thus with incurring significant direct and 
indirect costs. The presence of depression in patients with medical comorbidities increases the risks of 
myocardial infarction and decreases diabetes control, and adherence to treatment. The mechanism through 
which these effects are produced is still uncertain. Objectives of this study were to evaluate the metabolic 
alterations in female Wistar rats with induced depression, with and without administration of Agomelatine. 
The methods included two experiments. All data were analyzed by comparison with group I (control), and 
with each other. In the first experiment we induced depression by: exposure to chronic mild stress-group II; 
olfactory bulbectomy-group III; and exposure to chronic mild stress and hyperlipidic/ hyper caloric diet-
group IV. The second experiment was similar with the first but the rats received Agomelatine (0.16mg/ 
animal): group V (depression induced through exposure to chronic mild stress), VI (depression induced 
through olfactory bulbectomy) and VII (depression induced through exposure to chronic mild stressing 
hyperlipidic/ hypercaloric diet). Weight, cholesterol, triglycerides and glycaemia were measured at day 0 
and 28, and leptin value was measured at day 28. The results in the 1st experiment revealed significant 
differences (p<0.01) for weight and cholesterol in Group IV, for triglycerides in groups III and IV 
(p<0.001), and for glycaemia in group II. The 2nd experiment revealed significant differences (p<0.001) in 
group VII for weight and triglycerides, and in groups V and VI for triglycerides (p<0.01). In conclusion, 
significant correlations were found between high level of triglycerides and depression induced by chronic 
stress and olfactory bulbectomy. Agomelatine groups had a lower increase of triglycerides levels. 
  
Keywords: animal model, depression, agomelatine, metabolic alterations, cholesterol, 
triglycerides 
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Introduction  
Major depressive disorder (MDD) is among 
the most significant psychiatric disorders. The 
World Health Organization ranked depression as 
the fourth cause of disability around the world and 
estimated that it will take second place by 2020, 
after cardiovascular disorders (1, 2). Depression has 
a high global incidence and prevalence and is 
associated with a significant impact on the social 
and personal functioning (e.g., high rates of 
absenteeism, reduced productivity, familial 
disturbances) (3, 4), but also with important 
medical comorbidities (e.g., cardiovascular 
diseases, diabetes mellitus, dyslipidemia, obesity) 
(5, 6, 7).  
The association of depression with somatic 
comorbidities affects both the therapeutic approach 
and the quality of life of the patients. Despite vast 
research in the field, the relationship between 
depression and such comorbidities often remains 
unclear. For instance, obesity is considered a risk 
factor for depression (8), yet is also a comorbidity 
of depression. Many studies report a significant 
correlation between depression and metabolic 
syndrome, but it is still unclear whether this 
association is the cause-effect type or results from 
several common variables (5). Patients with 
depression have a higher risk for developing 
diabetes (4), and current epidemiological data show 
that at least one third of the patients with diabetes 
mellitus have clinically significant depressive 
symptoms (4). Depression is also a risk factor for 
cardiac mortality and morbidity but the potential 
mechanism that produces these effects remains 
uncertain (9). One possible explanation comes from 
the heart and soul study that revealed that the 
presence of MDD in out-patients with coronary 
heart disease decreases medication adherence (10). 
Such findings confirm earlier suggestions that 
depression is a risk factor for noncompliance with 
medical treatment (11) but it also reveals one of the 
possible mechanisms: untreated MDD decreases 
adherence to cardiovascular medication and thus 
patients remains unprotected, or too many drugs 
taken in the same time increases the risk of side 
effects and poor treatment adherence (10). Another 
pathway that links depression and cardiovascular 
diseases is represented by disruption of circadian 
sleep- wake cycles. Thus, disruption of sleep-wake 
cycle is a core feature of depressive disorder, which 
is associated with perturbation of hormonal 
secretion (12). But, disruption of circadian rhythm 
is also associated with increased risk for obesity, 
diabetes and cardiovascular disease (13). 
Difficulties in initiating and maintaining sleep were 
associated with increased incidence of diabetes in 
men (14). Also, a number of studies support an 
association between feeding regimens and quality 
of ingested food on one hand, and the circadian 
rhythm on the other hand (15).  
 
Aim. The objective of this study was to 
evaluate metabolic alterations that appear in rats 
with induced depression, with and without 
administration of Agomelatine, a melatonin analog. 
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The present data are drawn from a more extensive 
research project investigating animal models of 
induced depression.  
 
Materials and Methods 
The research was conducted in the Laboratory 
for Experimental Research of the Department of 
Physiology of the University of Medicine and 
Pharmacy “Iuliu Hatieganu” in Cluj-Napoca, and 
was approved by the Ethical Committee of the 
University. Female Wistar rats kept in adequate 
vivarium conditions were used. 
Two experimental analyses were conducted. 
The first analysis (Analysis 1) included four groups, 
of 10 rats each: group I (control); group II 
(depression induced through exposure to chronic 
mild-intensity stress – constant exposure of 120 
minute/ 24 hours, that is 5 minute/ hour, to a 
continuous auditory 5dB stimulus, automatically 
generated by a bell); group III (depression induced 
through olfactory bulbectomy); and group IV 
(depression induced through exposure to chronic 
mild-intensity stress and hyperlipidic/ hyper caloric 
diet). Groups I, II and III received adequate caloric 
diet – 20g/day/rat (proteins 18%, lipids 1.5% and 
fibers 5%), while group IV received the same 
amount and type of food to which 3ml pork 
fat/day/rat was added.  
The second analysis (Analysis 2) included 
three groups: group V (depression induced through 
exposure to chronic mild-intensity stress – same 
method as group II); group VI (depression induced 
through olfactory bulbectomy); and group VII 
(depression induced through exposure to chronic 
mild-intensity stress and hyperlipidic/hyper caloric 
diet – same method as group IV). The rats in 
Analysis 2 (groups V, VI and VII) received 
Agomelatine 0.16 mg/rat. 
Evaluation occurred baseline (T0) and after 28 
days (T28). At T0, weight (grams) and blood levels 
of cholesterol (mg/dL), triglycerides (mg/dL) and 
glycaemia/ glucose (mg/dL) were measured. At 
T28, weight (grams) and blood levels for 
cholesterol (mg/dL), triglycerides (mg/dL), 
glycaemia/glucose (mg/dL) and leptin (pg/ml) were 
measured. Statistical analysis was performed with 
Stats Direct software, version 2.7.2.  
For the descriptive statistics, indicators of 
centrality, localization and distribution were used to 
present the data. For testing the normal distribution, 
we used the Shapiro-Wilk test, while the variation 
was tested with F or Levene and/or Bartlett tests. 
We used the t (Student) test for data with normal 
distribution and Mann-Whitney (U) non-
parametrical tests (for two non-paired variables) or 
Wilkoxon (for two paired variables) for data with 
non-uniform distribution and rankings.  
For analyzing three or more variables we used 
the ANOVA test for normal distribution and 
Kruskal-Wallis for non-uniform distribution. The 
level for significance was set at α= 0.05 (5%), α= 
0.01 (1%) or α= 0.001. 
 
Results 
An overview of the variables values of the 
groups included in Analysis 1 is showed in Table 1.
Maria-Gabriela Puiu.  et al. 
175 
 
Table 1. Comparison between the variables values at T0 and T28 for the groups included in Analysis 1 
Group Variable Time Mean ES Median SD Min. Max. 
I 
Weight 
T0 160.4 2.39 158.5 7.56 150.0 172.0 
T28 160.4 2.39 158.5 7.56 150.0 172.0 
Cholesterol 
T0 161.8 2.04 162.0 6.44 152.0 169.0 
T28 162.6 1.23 162.0 3.89 156.0 170.0 
Triglycerides 
T0 164.4 2.29 166.5 7.24 153.0 172.0 
T28 165.0 2.24 168.5 7.07 154.0 172.0 
Glycaemia 
T0 76.6 1.41 75.5 4.45 71.0 84.0 
T28 77.8 1.42 77.0 4.49 72.0 84.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 1903.16 53.07 1979.10 167.83 1668.40 2071.40 
II 
Weight 
T0 156.4 1.92 154.0 6.08 150.0 166.0 
T28 158.2 1.62 158.5 5.12 151.0 168.0 
Cholesterol 
T0 185.8 1.79 185.5 5.67 177.0 193.0 
T28 187.4 1.62 188.5 5.13 178.0 194.0 
Triglycerides 
T0 178.6 2.57 178.0 8.11 168.0 191.0 
T28 182.8 2.72 183.0 8.60 172.0 194.0 
Glycaemia 
T0 93.4 1.67 95.0 5.27 86.0 101.0 
T28 111.4 2.32 110.5 7.34 102.0 121.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 2706.12 287.45 2477.50 908.99 1652.80 4229.80 
III 
Weight 
T0 159.4 1.23 160.5 3.89 152.0 164.0 
T28 159.6 1.17 160.5 3.69 152.0 164.0 
Cholesterol 
T0 172.6 1.38 173.5 4.35 164.0 178.0 
T28 171.8 4.08 169.0 12.91 158.0 199.0 
Triglycerides 
T0 181.6 1.85 181.5 5.83 172.0 190.0 
T28 247.8 3.85 251.0 12.17 227.0 262.0 
Glycaemia T0 87.4 1.92 87.5 6.06 79.0 97.0 
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T28 90.8 1.98 88.5 6.25 82.0 100.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 2365.24 177.54 2285.30 561.44 1665.40 3357.00 
IV 
Weight 
T0 160.0 2.58 164.5 8.15 147.0 167.0 
T28 307.8 2.28 304.5 7.21 300.0 320.0 
Cholesterol 
T0 156.8 2.02 159.5 6.39 144.0 163.0 
T28 192.4 10.77 187.5 34.07 154.0 254.0 
Triglycerides 
T0 203.8 10.88 196.0 34.41 167.0 263.0 
T28 313.4 11.41 310.0 36.08 265.0 386.0 
Glycaemia 
T0 112.6 1.73 111.0 5.48 107.0 125.0 
T28 113.0 6.32 119.5 19.99 72.0 131.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 1908.44 163.51 1859.70 517.07 1058.80 2930.60 
 
Statistical analysis of the variables for pairs 
(T0-T28) showed highly significant differences 
(p<0.001) in groups III and IV for triglycerides and 
in group II for glycaemia, very significant 
differences (p<0.01) in group IV for weight and 
cholesterol and significant differences (p<0.05) in 
group II for triglycerides (Table 2). Table 3 shows 
the variables values of the groups included in 
Analysis 2. 
 
Table 3. Comparison between the variables values at T0 and T28 for the groups included in Analysis 2 
Group Variable Time Mean ES Median SD Min. Max. 
V 
Weight 
T0 161.2 2.24 159.0 7.08 151.0 172.0 
T28 161.3 1.63 159.5 5.16 157.0 173.0 
Cholesterol 
T0 182.0 2.04 180.0 6.46 175.0 194.0 
T28 184.4 1.71 183.5 5.40 177.0 192.0 
Table 2. Levels of significance (p-values) of the 
variables for each group (T0-T28) in Analysis 1 
(significant values in bold) 
Variable 
(Group) 
Weight Cholesterol Triglycerides Glycaemia 
I ― 0.7337 0.3750 0.2284 
II 0.6250 0.3963 0.0248 < 0.001 
III 0.5086 0.7695 < 0.001 0.1343 
IV 0.002 0.002 < 0.001 0.7695 
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Triglycerides 
T0 164.0 1.66 163.0 5.25 157.0 172.0 
T28 170.4 2.07 171.0 6.54 160.0 178.0 
Blood sugar 
T0 103.6 2.08 101.0 6.57 94.0 112.0 
T28 121.6 1.61 123.0 5.08 113.0 127.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 2241.8 266.26 2300 841.99 1049.0 3897.4 
VI 
Weight 
T0 159.8 2.10 162.5 6.65 147.0 167.0 
T28 159.9 2.35 163.0 7.43 147.0 167.0 
Cholesterol 
T0 168.2 1.63 169.0 5.16 158.0 174.0 
T28 170.6 2.86 171.0 9.03 159.0 183.0 
Triglycerides 
T0 174.4 2.01 176.0 6.35 166.0 182.0 
T28 222.8 2.53 224.0 7.99 210.0 232.0 
Glycaemia 
T0 82.6 1.57 81.5 4.97 77.0 91.0 
T28 90.0 0.70 89.5 2.21 87.0 94.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 2487.64 141.33 2523.3 446.92 1885.4 3152.8 
VII 
Weight 
T0 159.6 2.09 158.0 6.60 151.0 169.0 
T28 299.4 3.65 299.5 11.54 280.0 315.0 
Cholesterol 
T0 157.8 2.98 156.0 9.43 144.0 171.0 
T28 173.0 5.55 172.5 17.56 150.0 201.0 
Triglycerides 
T0 173.2 4.65 175.5 14.70 153.0 194.0 
T28 201.8 6.56 202.0 20.75 164.0 228.0 
Glycaemia 
T0 96.4 1.50 97.5 4.7422 87.0 102.0 
T28 96.2 5.52 97.5 17.4662 74.0 122.0 
Leptin 
T0 ― ― ― ― ― ― 
T28 2075.04 180.66 2169.3 571.30 1058.8 2801.8 
   
      
Statistical analysis of the variables for pairs (T0-
T28) showed highly significant differences 
(p<0.001) in group VII for weight and triglycerides, 
very significant differences (p<0.01) in groups V 
and VI for triglycerides and significant differences 
(p<0.05) in group VII for cholesterol (Table 4). 
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Discussion
The significant increase of weight and 
cholesterol is related to the quantity and content of 
the diet. In the present study, the increase of 
triglycerides was found in the groups with chronic 
mild-intensity stress, independent of the diet type, 
in the group with olfactory bulbectomy without 
Agomelatine, but not in the control group. This 
result confirms the available data indicating a 
significant correlation between depression and 
triglycerides levels (16,17,18). Agomelatine 
correlated with significantly smaller amplitude in 
the increase of triglycerides. In one study evaluating 
the effect of melatonin administration on 
developing metabolic syndrome in male Wistar rats 
with high calorie diet, melatonin administration was 
associated with reduced weight gain, visceral 
adiposity, blood triglyceride, and insulin level (19). 
In another study evaluating the influence of 
melatonin administration on dyslipidemia and 
systolic hypertension using young male Zucker 
diabetic fatty rats, melatonin administration was 
associated with reduced mean weight gain without 
influencing food ingestion and decreased levels of 
triglyceride (20). Possible mechanisms involve the 
effect of melatonin on circadian rhythm, giving the 
links that exist between the circadian system and 
obesity, diet and depression (21, 22).  
The results for leptin levels are difficult to 
interpret based on the current study design (no 
determination at T0) and the literature reports an 
inconsistent relation between depression and leptin. 
Some studies reported that patients with major 
depressive disorder have lower leptin levels 
compared to healthy controls with similar body 
mass index (23,24), while others have reported 
higher levels of leptin in women with depression 
(25,26,27). In one study, rats which were subject to 
chronic unpredictable stress and chronic social 
defeat presented low level of leptin (28). In 
addition, in the previously mentioned study, leptin 
administration had an antidepressant like effect 
(28). 
Such findings should be also discussed in the 
context of ACTH and cortisol influence on the 
hormonal and metabolic status, because it is known 
from previous studies that the circadian rhythm of 
cortisol secretion disappears both in Cushing 
disease and in major depressive episode (29). Thus, 
this relationship might also impact glucose and lipid 
metabolisms. 
 
Conclusions 
The results of the present study support the 
correlation between the increase of triglycerides and 
experimentally induced depression in rats through 
chronic stress and olfactory bulbectomy. The 
administration of Agomelatine was associated with 
Table 4. Levels of significance of the variables for each 
group (T0-T28) in Analysis 2 (statistically significant values 
in bold) 
Variable 
Group 
Weight Cholesterol Triglyce-
rides 
Glycaemia 
V 0,8125 0,1114 0,0071 < 0.001 
VI 0,3594 0,3270 0,002 < 0.001 
VII < 0.001 0,0126 < 0.001 0,9723 
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smaller amplitude of the increase of triglycerides. 
Except the groups with hyperlipidic diet, 
experimentally induced depression was not 
associated with an increase in cholesterol levels. 
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